# OnCo record paper-roberts-venetoclax-relapsed-cll-nejm-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-roberts-venetoclax-relapsed-cll-nejm-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-roberts-venetoclax-relapsed-cll-nejm-2016" ;
  schema:name "Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia"@en ;
  schema:description "The first-in-human study of venetoclax, the BCL-2 blocker that grew from a discovery at the Walter and Eliza Hall Institute in Melbourne. Four in five people with relapsed CLL responded."@en ;
  schema:url <https://onco.cc/key-papers/paper-roberts-venetoclax-relapsed-cll-nejm-2016/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1513257>, <https://pubmed.ncbi.nlm.nih.gov/26639348/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1513257> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/> ;
  onco:institutions <https://onco.cc/institutions/wehi/>, <https://onco.cc/institutions/peter-mac/> ;
  onco:trials <https://onco.cc/trials/murano/> ;
  onco:people <https://onco.cc/people/andrew-roberts/>, <https://onco.cc/people/john-seymour/> .